Lurasidone in Schizophrenia Management: A Comprehensive 12-Week Post-Marketing Surveillance Study in Chinese Patients.

Wei YM, Yang XD, Wang CS, Wang LL, Deng HL, Sang H, Xue AL, Zhu DM, Li YM, Liu XJ, Li HY, Shen YF, post-market surveillance investigators

Open source

DOI: 10.2147/ndt.s588526
Published: 2026
Container: Neuropsychiatric disease and treatment
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2147/ndt.s588526,
  title = {Lurasidone in Schizophrenia Management: A Comprehensive 12-Week Post-Marketing Surveillance Study in Chinese Patients.},
  author = {Wei YM and Yang XD and Wang CS and Wang LL and Deng HL and Sang H and Xue AL and Zhu DM and Li YM and Liu XJ and Li HY and Shen YF and post-market surveillance investigators},
  year = {2026},
  journal = {Neuropsychiatric disease and treatment},
  doi = {10.2147/ndt.s588526},
  url = {https://doi.org/10.2147/ndt.s588526}
}

RIS

TY  - JOUR
TI  - Lurasidone in Schizophrenia Management: A Comprehensive 12-Week Post-Marketing Surveillance Study in Chinese Patients.
AU  - Wei YM
AU  - Yang XD
AU  - Wang CS
AU  - Wang LL
AU  - Deng HL
AU  - Sang H
AU  - Xue AL
AU  - Zhu DM
AU  - Li YM
AU  - Liu XJ
AU  - Li HY
AU  - Shen YF
AU  - post-market surveillance investigators
PY  - 2026
JO  - Neuropsychiatric disease and treatment
DO  - 10.2147/ndt.s588526
UR  - https://doi.org/10.2147/ndt.s588526
ER  -

APA

YM, W., XD, Y., CS, W., LL, W., HL, D., H, S., AL, X., DM, Z., YM, L., XJ, L., HY, L., YF, S., & investigators, P. S. (2026). Lurasidone in Schizophrenia Management: A Comprehensive 12-Week Post-Marketing Surveillance Study in Chinese Patients.. Neuropsychiatric disease and treatment. https://doi.org/10.2147/ndt.s588526

Source records

pubmed · retrieved 2026-09-26T17:40:51.849Z